Nidec Shares Plunge on Report of $6.3 Billion Impairment Charge 
Hong Kong Home Prices Stabilize in August After July Decline 
TikTok Reaches $100 Million Alabama Settlement Over Child Safety Claims 
Suzuki Targets Faster Car Development to Keep Pace With Chinese Rivals 
China Consumer Stocks Near Decade Lows as AI Shares Surge 
South Korea Tax Windfall Could Top 50 Trillion Won on Chip Boom 
Vitalik Buterin Says Hegota Could Be Ethereum’s Last Conventional Fork 
Oil Prices Jump Nearly 3% as Iran Holds Firm on Hormuz Conditions 
BlackRock’s Rick Rieder Favors Bonds Over Stocks as Treasury Yields Surge 
OpenAI Investigates Rogue AI Agents After Data Leaks and Security Incidents 
Trump to Ease U.S. Fuel-Economy Standards 
Asian Stocks Fall as Oil Surge, Bond Yields and AI Concerns Hit Markets 
Oura IPO Draws Strong Demand Ahead of $2.2 Billion Offering 
U.S. Stock Futures Fall as Iran, Oil and AI Risks Rattle Markets 
China Cuts Tariffs on U.S. Farm Goods but Excludes Soybeans 
Europe’s AI Data Centre Boom Strengthens Case for Nuclear Power 
Almonty Industries Shares Jump 8% After Stifel Sets $25 Target 
Add as a preferred source on Google
SK pharmteco, a global Contract Development and Manufacturing Organization (CDMO) and a subsidiary of SK Inc., just launched its second production plant in France. With this new facility, it has now increased its production of viral vectors to double.
The Korea Economic Daily, Yposkesi, an SK pharmteco's subsidiary and one of Europe's largest CDMOs for viral vector manufacturing in Cell and Gene Therapies, finished up the construction of the new 5,000 square meter facility for industrial bioproduction for cell and gene therapy.
It was added that Yposkesi is planning to launch the commercial operations of the vector factory in 2024. A total of $65.3 million was put in for the construction of this facility. The companies may now produce up to 75 batches of cell and gene therapy products per year.
These productions are said to be one of the most advanced personalized types of medicine for the treatment of rare disorders and serious illnesses. The demand for such treatments is growing as they were proven to be effective and with fewer side effects too. These give good results since they are made with patients' own genes and cells.
"It is with great pleasure and pride that today we open the new Yposkesi viral vector manufacturing facility. This twin site enables us to stay up to pace with demand by producing larger quantities of C> products approved for commercialization," Yposkesi's chief executive officer, Alain Lamproye, said in a press release. "The facility's state-of-the-art design will allow us, in collaboration with our clients, to manufacture advanced therapies more efficiently and cost-effectively in line with their C> pipelines and commitments, making these treatments more accessible to patients."
SK Inc. head of Bio Investment Center, Kim Yeon Tae Kim, also said they "anticipate Yposkesi to become a leading global Cell and Gene Therapy Contract Development and Manufacturing Organization through the synergy achieved with the Center for Breakthrough Medicines (CBM), a US-based cell and gene therapy CDMO and a subsidiary of SK pharmteco."
Photo by: SK Inc. Press Release
